34 results about "Bronchus" patented technology

The invention relates to the field of medical image processing, in particular to a pulmonary nodule natural orifice optimal path intelligent planning system which comprises a data preprocessing module, a bronchus three-dimensional segmentation module, a pulmonary nodule segmentation module, a differential geometric path search module, a path evaluation module and a doctor interaction module. The differential geometric path search module comprises a Riemannian curvature flow modeling unit, a multi-scale Gaussian curvature constraint unit and a geodesic curvature self-adaptive correction unit, can model bronchus into a Riemannian manifold, applies curvature flow optimization, and combines a multi-scale decomposition strategy and a geodesic theory to obtain a geodesic curvature self-adaptive correction model; precise description and optimal path planning of bronchial geometrical characteristics are realized, the path evaluation module provides multi-dimensional evaluation of blood vessel avoidance, diameter adaptation and curvature safety, and the doctor interaction module supports three-dimensional visualization and real-time path editing. The problem that a traditional Euclidean space algorithm is insufficient in description of complex forms of bronchus is solved by introducing a differential geometry theory.

Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are commonly treated with β2-adrenergic receptor agonists that activate intracellular signaling pathways to induce airway relaxation. However, current therapies are limited by progressive receptor desensitization, or tachyphylaxis, largely attributed to β-arrestin recruitment. This desensitization reduces therapeutic efficacy over time and complicates long-term disease management, resulting in suboptimal outcomes for patients who rely on bronchodilators for daily symptom control. Disclosed herein are pharmaceutical compositions comprising biased agonists and their methods of use, which minimally activate recruitment of beta-arrestin2.

The invention discloses a segmentation modeling method for improving bronchial branch identification precision, and belongs to the technical field of medical image processing and respiratory tract three-dimensional reconstruction. According to the method, high-resolution acquisition is performed on a respiratory tract CT image, and preliminary segmentation of a tracheal tree is completed in combination with gray threshold setting and a region growing algorithm; and a reference line is introduced at the bifurcation, and dynamic region growth based on density gradient is adopted, so that refined identification of the sixth-level bronchial branch is realized. And then carrying out iteration correction on the generated model for multiple times, manually comparing anatomical features to delete pseudo branches and complement missing branches, and completing smoothing and NURBS curved surface construction in Geomagic software. And finally, splicing and fusing the bronchial branch model and an independently generated upper respiratory tract model to obtain a complete three-dimensional respiratory tract combination model, and ensuring that the error between the three-dimensional respiratory tract combination model and an original CT image is controlled within 0.8 mm through deviation analysis. According to the method, the recognition precision of the fine bronchial branches can be remarkably improved, the defect of misrecognition or missing division of traditional threshold segmentation is overcome, and the obtained three-dimensional model can be used for aerosol drug deposition simulation, respiratory system disease diagnosis, surgical planning and design and evaluation of personalized inhalation devices.

The invention discloses a broncholung lavage fluid composition for treating non-small cell lung cancer, and relates to the technical field of cancer treatment. The preparation method of the bronchus lung lavage fluid composition for treating the non-small cell lung cancer comprises the following steps: S1, performing metagenome sequencing on a BALF sample, S2, grouping by R / NR based on differential strains obtained in S1 to obtain core bacteria, performing single-strain Kaplan-Meier survival analysis on the strains, and determining the survival rate of the single-strain Kaplan-Meier to obtain the bronchus lung lavage fluid composition for treating the non-small cell lung cancer. Finally, seven key microorganisms, namely bronchopulmonary lavage fluid combinations, which are remarkably related to immunotherapy PFS are locked; s3, determining the relationship between the seven key BALF bacteria and the existing immune therapeutic effect marker; and S4, verifying the generation conditions of IL6, IL8 and RANTES cytokines promoted by the seven strains through an in-vitro cell experiment, and revealing the activation and enhancement effects of the seven strains on immune cell functions. According to the invention, the immunotherapy effect of the non-small cell lung cancer patient can be promoted to be improved by combining a plurality of beneficial specific microorganisms in an airway administration mode. In conclusion, the method has a good application prospect.

The application provides a lung segment bronchus catheter, which comprises a catheter tail end ventilation and suction interface, a cuff inflation device, an outer tube, an inner tube, a front end cuff and a guide end formed by the inner tube; the cuff is annularly arranged on the outer surface of the catheter head, and is in the form of a ring ball wrapped around the inner tube in the inflated state; the cuff inflation interface and the cuff inflation conduit are communicated between the gap between the outer tube and the inner tube at the catheter tail and lead to the cuff; the catheter ventilation and suction interface is communicated with the inner tube and the guide end formed by the inner tube, and a guide wire is arranged in the catheter ventilation and suction interface to form a straight lumen. The catheter can enter the target lung segment or sub-lung segment bronchus through the operation channel of the bronchoscope, the inflated cuff seals the airway cavity around the lung segment bronchus catheter cavity, then the guide wire is pulled out from the lung segment bronchus catheter cavity, the target lung segment or sub-lung segment is inflated through the catheter ventilation and suction interface, so that the anatomical range of the target lung segment or sub-lung segment after ventilation is revealed, the technical problem that a thoracic surgeon cannot accurately identify the anatomical range of the target lung segment in the operation is effectively solved, and the thoracic surgery anatomical partial lobectomy operation is facilitated.

The present disclosure provides methods, uses, and pharmaceutical compositions with utility in the treatment of acute lung injuries or chronic lung diseases including, bronchopulmonary dysplasia and exacerbations of bronchopulmonary dysplasia.

The present invention provides a mutant adeno-associated virus serotype 1 (AAV1) capsid protein, wherein the mutant has an amino acid substitution at a specific position compared to the amino acid sequence of the wild-type AAV capsid protein; a nucleic acid encoding the mutant AAV1 capsid protein; a recombinant AAV1 vector comprising the nucleic acid encoding the mutant AAV1 capsid protein; and a pharmaceutical composition comprising the vector. In particular, a recombinant viral vector comprising the nucleic acid encoding the mutant AAV1 capsid protein enhances transgene expression in the lungs and bronchi when delivered in an aerosol state through the bronchi, making it useful for the prevention or treatment of respiratory diseases.

This invention provides a liposomal sustained-release composition of a bronchodilator for treating lung diseases. The liposomal bronchodilator comprises liposomes encapsulating the bronchodilator. The bronchodilator is stably encapsulated in the liposomes, and the resulting liposomal bronchodilator has been shown to be stably nebulized or aerosolized for administration via inhalation to treat individuals in need.

The utility model relates to a melamine pulse batch-type purging separation device, the output end is connected with a pipeline system, the device comprises a branch air pipe, a flow deflector is arranged at the connecting position of the pipeline system and the branch air pipe, the flow deflector wraps the outlet of the branch air pipe and forms a flow guide cavity, the flow deflector comprises an arc-shaped part and a straight line part, and the arc-shaped part is connected with the straight line part. And the straight line part is parallel to the flow direction of gas in the pipeline system. According to the utility model, the valve is intermittently purged through the branch air pipe pulse, so that the interior of the valve body is ensured to be clean, and the valve acts freely and is closed tightly; meanwhile, the flow deflectors are arranged, the flow direction of gas can be changed, the gas is forced to be parallel to the linear part, and therefore the gas flowing out of the branch gas pipes and the gas flow direction in the pipeline system are the same, and the pulse effect of compressed gas can be reserved.

Described is a method for improving the condition of a patient suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), comprising administering to the patient by inhalation from 2.5 million international units (MIU) to 6 MIU of colistimethate sodium (CMS) once a day for a period of at least 28 days. Other embodiments are also disclosed.

The invention relates to the field of traditional Chinese medicines, in particular to novel application of a Sweeping Tianhu lung-clearing and cough-relieving composition in treatment of chronic obstructive pulmonary disease. Animal experiment studies show that the Sweetio lung-clearing and cough-relieving composition can significantly improve the lung function of COPD mice and inhibit bronchial abnormal remodeling. The action mechanism of the composition is related to inhibition of lung tissue cell apoptosis, alleviation of inflammatory cell infiltration and improvement of abnormal remodeling of bronchus, which indicates that the Sweeping Litu composition for clearing away lung-heat and relieving cough has obvious pharmacological activity of resisting COPD (chronic obstructive pulmonary disease).

The invention relates to medical uses of alvelestat, and pharmaceutically acceptable salts thereof, in the treatment of non-cystic fibrosis bronchiectasis.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention relates to the field of biological medicine, in particular to a biomarker for diagnosing pneumonia. The invention provides application of a biomarker in preparation of a kit for diagnosing pneumonia and / or evaluating the curative effect of pneumonia, and is characterized in that the biomarker comprises ADA2 in bronchoalveolar lavage fluid, and the kit is used for quantitatively detecting the content of ADA2 in a bronchoalveolar lavage fluid sample of a subject. By detecting the content of ADA2 in a bronchoalveolar lavage fluid sample of a subject, whether the subject is a severe pneumonia patient or not can be quickly and accurately diagnosed.

The invention provides a budesonide inhalable solution composition and a preparation method thereof. Compared with an existing budesonide suspension preparation, the budesonide inhalable solution composition provided by the invention is stable in property; the budesonide and the terbutaline sulfate contained in the solution composition have excellent delivery performance and pharmacokinetic properties, can be better distributed on the surface of bronchus or lung, and can be quickly dissolved and absorbed, quickly exert efficacy and relieve asthma symptoms. The budesonide inhalable solution composition provided by the invention is simple in preparation method and easy for industrial production.

Aspects of the present disclosure provide compositions comprising NEK10 for example, wild-type NEK10 or a hyperactive NEK10 mutant such as NEK10S684D, and methods of using such for treating a respiratory disorder such as bronchiectasis.

The utility model relates to a system for eliminating, reducing, clearing and sucking sputum and treating waste sputum. The system comprises a sputum tank, a liquid medicine tank and a liquid tank. The inner cavity of the tank is connected with a positive-negative pressure air source, a water source and a sputum suction and drainage pipe. The device further comprises a foot switch, an electromagnetic valve, a pressure regulator, a controller, an electromagnetic vibrator, an expiration electromagnetic valve switch, a trachea cannula, a double-channel sputum suction tube and the like. According to the principle, during sputum excretion, resonance is generated during lung expiration of a patient by controlling the switching frequency of the electromagnetic valve and vibration of the vibrator in a timing mode, lung secretions continuously overflow, and the treatment effects of sputum excretion, inflammation diminishing and detoxification are achieved. During sputum suction, the sputum suction tube is inserted into a trachea and a bronchus within more than ten seconds, and a trace amount of liquid is used for reducing and clearing sputum and synchronously sucking sputum, so that the ventilation and oxygen supply effects are improved, and the sputum suction tube plays a crucial role in rescuing the life of a critically ill patient. Sucked sticky sputum is added with water, stirred and discharged into a sewage station, replacement and destruction of a sputum suction bottle are omitted, cross infection is prevented, and environment-friendly biological safety scientific management is facilitated.

The invention provides an indoor pathogen aerosol transmission risk quantitative evaluation and closed-loop control method, and relates to the technical field of public health environment engineering.The indoor pathogen aerosol transmission risk quantitative evaluation and closed-loop control method comprises the steps that multi-dimensional environment parameters such as spatial layout, ventilation operation parameters, pathogen characteristics, personnel activity and protection equipment parameters are obtained; obtaining an air concentration distribution field and a surface concentration distribution field through numerical calculation; respectively constructing dose calculation and dose response models of the contact path and the inhalation path, wherein the inhalation path divides the respiratory tract into at least an upper respiratory tract region, a tracheal bronchus region and a pulmonary alveolar region, and calculating a partitioned deposited dose; monte Carlo simulation is adopted to represent the randomness of key parameters, the contact infection probability, the inhalation infection probability and the comprehensive infection risk are output, a ventilation control set value or a control instruction meeting a risk threshold value is generated, and accurate evaluation and closed-loop control of the indoor pathogen aerosol transmission risk can be achieved.

The application discloses a lung deep layer targeted delivery method and a micro robot cluster, and comprises the following steps: preparing microgel particles containing magnetic microparticles, developing particles and cargos, and combining the prepared microgel particles to obtain the micro robot cluster; controlling the motion, climbing and reconstruction of the micro robot cluster in a non-fluid environment to realize the motion in a pipe environment with holes; controlling the motion of the micro robot cluster in a lung sample under the guidance of X-ray to deliver the micro robot cluster to a target bronchus of the lung sample; or controlling the delivery of the micro robot cluster in a target lung under the guidance of computer tomography imaging, and releasing the wrapped cargos in the target bronchus; and the micro robot cluster can realize the targeted delivery in the lung environment full of air, the lung environment with a mucous layer and a target bronchus in the lung deep layer.

An inhalation powder containing 24.1 μg of glycopyrronium bromide and 12.7 μg of formoterol fumarate dihydrate per unit dose is disclosed. The powder shows a clear bronchodilatory effect in patients with COPD after twice daily administration. After repeated administration, the lung function of the patients is significantly improved.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

The application discloses a kind of human whole lung model in particle deposition numerical simulation method, it is related to biomedical engineering and computational fluid dynamics technical field.The method includes: constructing including upper respiratory tract, bronchus and lung alveolus human whole lung geometric model, and is divided into corresponding area;In inspiration stage, inject particle from upper respiratory tract entrance, simulate particle movement, record the escape, suspended and deposited particles of bronchial region;Lung alveolus region adopts dynamic grid technology to simulate expansion and shrinkage in breathing cycle, stores exhaled particle;In expiration stage, the lung alveolus exhaled particle is introduced into bronchus, and is combined with suspended and deposition information and is simulated progressively upwards, until particle is exhaled from upper respiratory tract, complete whole breathing cycle particle deposition simulation, obtain particle deposition rate.The method can accurately simulate the deposition process of particle in whole lung, and provide support for inhaled drug delivery and health risk assessment.

This disclosure provides pharmaceutical preparations, products, and methods relating to ARINA-1 for use in treating patients with chronic inflammatory lung diseases, such as lung transplant, cystic fibrosis (CF), non-CF bronchiectasis, chronic obstructive pulmonary disease (COPD, and other inflammatory lung diseases.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.

The invention therefore provides methods of treating a respiratory disease characterized by mucus hyper-secretion comprising administering to a human patient in need of such treatment a gamma secretase inhibitor (GSI), wherein the administration of a GSI is effective in reducing mucus in such patient's lungs or inhibiting mucus accumulation in said patient's lungs. In some embodiments, the methods of the invention are effective in treating a respiratory disease selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesis, chronic bronchitis, asthma, idiopathic and secondary bronchiectasis, bronchiolitis obliterans, idiopathic pulmonary fibrosis, respiratory infection and mucus accumulation in response to infection. Methods of the invention further include methods of treating cystic fibrosis wherein a GSI is administered to a patient being administered or in need of a CFTR modulator, wherein the mucus in such patient's lungs is reduced or mucus accumulation in such patient's lungs is inhibited.

The utility model relates to a kind of bronchus blocking catheter of anti-displacement blockage, the top end of the blocking catheter movably connects with the fixed strip for sealing and tightening cover tight component to blocking catheter;The clamping device includes the clamping component for clamping and fixing bronchus in cover tight device, and the driving component for driving two clamping components to move in opposite directions is arranged in cover tight device. By cover cap insertion to the top end of blocking catheter, then by two rotating fixed strip is clamped in clamping strip, cover cap can be covered and tightened, three elastic strips can be used to clamp and fix bronchus, then by hand wheel driving bidirectional screw rod is rotated, two threaded sleeve plates can be made along the two threaded portions on the rod body of bidirectional screw rod to bronchus close, while fixed sleeve plate can move along guide rod, and bronchus is clamped and fixed, to prevent bronchus from the risk of loosening and falling.

An implantable artificial bronchus (IAB) is provided that is used for the treatment of chronic obstructive pulmonary diseases, such as pulmonary emphysema. The implantable artificial bronchus can be made with silicone or nitinol, and has a tapered cylindrical shape. Additional embodiments of this apparatus may be further associated with a one-way valve on the nozzle of the IAB.

A device for treating respiratory conditions is disclosed. The device generates electrical pulses directed to a region of the spinal cord column. The electrical pulses provide a neuromodulation that prevents bronchoconstriction to mitigate symptoms associated with chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

This invention discloses a bronchus classification method and apparatus based on graph structures. The method includes: acquiring lung image sample data; extracting a binarized segmentation mask for the bronchi to obtain a bronchus mask image; inputting this image into a convolutional neural network for prediction to obtain high-dimensional convolutional features and a first bronchus segmentation result; performing skeletonization processing on the bronchus mask image to obtain point-by-point coordinate features; combining the point-by-point coordinate features and the high-dimensional convolutional features and inputting them into a point-voxel graph neural network for prediction to obtain a second bronchus segmentation result; iteratively training the convolutional neural network and the point-voxel neural network based on the first and second bronchus segmentation results, and then using the trained convolutional neural network to segment actual lung images. Utilizing the point-voxel neural network to guide the learning process of the convolutional neural network through convolutional features can improve classification performance.

A method comprises identifying a subject as having pulmonary hypertension, and responsively to the identifying, implanting an obstructor within a bronchus of a lung of the subject such that, during each exhalation by the subject, the obstructor partially obstructs exhaled air from flowing past the obstructor. Other embodiments are also described.